New studies deepen understanding of Alzheimer’s pathology and potential therapies. Researchers from Aarhus University identified mutant SORLA protein defects impairing neurotrophic exosome release, implicating it in familial Alzheimer’s disease. Remynd NV reported positive phase IIa clinical data for REM-127, a new agent restoring neuronal calcium homeostasis to reduce tau pathology and improve cognition. These advances contribute to therapeutic strategies for AD and neurodegeneration.